Optimization of erlotinib for the treatment of patients with advanced non small cell lung cancer: an Italian randomized trial.
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Erlotinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms TAILOR
- 06 Jun 2017 Results (n=123) assessing predictive value of concurrent mutation of KRAS and LKB1 for resistance to erlotinib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 24 Jul 2015 Results published in the Annals of Oncology.
- 02 Jun 2015 Results of pooled analysis of PROSE, TAILOR and DELTA trial presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History